| Market Cap | 25.54M | P/E | - | EPS this Y | 51.40% | Ern Qtrly Grth | - |
| Income | -53.45M | Forward P/E | -1.46 | EPS next Y | 57.30% | 50D Avg Chg | 24.00% |
| Sales | - | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -3.00% |
| Dividend | N/A | Price/Book | 0.41 | EPS next 5Y | 29.90% | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 6.67 | Shares Outstanding | 3.21M | 52W Low Chg | 148.00% |
| Insider Own | 1.69% | ROA | -43.03% | Shares Float | 1.55M | Beta | 0.93 |
| Inst Own | 76.93% | ROE | -174.90% | Shares Shorted/Prior | 49.17K/59.62K | Price | 0.85 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 88,429 | Target Price | 33.00 |
| Oper. Margin | - | Earnings Date | Aug 12 | Volume | 46,358 | Change | 2.91% |
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
